News Column

Studies from Research Institute in the Area of Nanomedicine Reported

June 20, 2014

By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Nanomedicine are presented in a new report. According to news reporting originating in Beijing, People's Republic of China, by NewsRx journalists, research stated, "Compelling evidence suggests that reactive oxygen species (ROS) play a pivotal role in disk degeneration. Fullerol nanoparticles prepared in aqueous solution have been demonstrated to have outstanding ability to scavenge ROS."

The news reporters obtained a quote from the research from Research Institute, "In this report, in vitro and in vivo models were used to study the efficacy of fullerol in preventing disk degeneration. For in vitro experiments, a pro-oxidant H2O2 or an inflammatory cytokine interleukin (IL)-1 beta was employed to induce degenerated phenotypes in human nucleus pulposus cells encapsulated in alginate beads, and fullerol was added in the culture medium. For the animal study, an annulus-puncture model with rabbit was created, and fullerol was injected into disks. It was shown that cytotoxicity and cellular ROS level induced by H2O2 were significantly diminished by fullerol. IL-1 beta-induced nitric oxide generation in culture medium was suppressed by fullerol as well. Gene-profile and biochemical assays showed that fullerol effectively reversed the matrix degradation caused by either H2O2 or IL-1 beta. The animal study delineated that intradiskal injection of fullerol prevented disk degeneration, increasing water and proteoglycan content and inhibiting ectopic bone formation."

According to the news reporters, the research concluded: "These results suggest that antioxidative fullerol may have a potential therapeutic application for disk degeneration."

For more information on this research see: Antioxidative nanofullerol prevents intervertebral disk degeneration. International Journal of Nanomedicine, 2014;9():2419-2430. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Nanomedicine).

Our news correspondents report that additional information may be obtained by contacting X.L. Yang, Res Inst Beijing Tongrentang Co Ltd, Beijing, People's Republic of China. Additional authors for this research include L. Jin, L. Yao, F.H. Shen, A.L. Shimer and X.D. Li.

Keywords for this news article include: Asia, Beijing, Nanomedicine, Therapeutics, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Medicine Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters